Literature DB >> 12554695

Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation.

Yong-Jun Yin1, Zaidoun Salah, Myriam Maoz, Sharona Cohen Even Ram, Shalom Ochayon, Gera Neufeld, Shulamit Katzav, Rachel Bar-Shavit.   

Abstract

The formation of new blood vessels is a critical determinant of tumor progression. We find that Par1 gene expression plays a central role in blood vessel recruitment in animal models. By in vivo injection of either Matrigel plugs containing Par1-expressing cells or of rat prostatic carcinoma cells transfected with tetracycline-inducible Par1 expression vectors, we show that Par1 significantly enhances both angiogenesis and tumor growth. Several vascular endothelial growth factor (VEGF) splice forms are induced in cells expressing Par1. Activation of PAR1 markedly augments the expression of VEGF mRNAs and of functional VEGFs as determined by in vitro assays for endothelial tube alignment and bovine aortic endothelial cell proliferation. Because neutralizing anti-VEGF antibodies potently inhibited Par1-induced endothelial cell proliferation, we conclude that Par1-induced angiogenesis requires VEGF. Specific inhibitors of protein kinase C (PKC), Src, and phosphatidylinositol 3-kinase (PI3K) inhibit Par1-induced VEGF expression, suggesting the participation of these kinases in the process. We also show that oncogenic transformation by genes known to be part of PAR1 signaling machinery is sufficient to increase VEGF expression in NIH 3T3 cells. These data support the novel notion that initiation of cell signaling either by activating PAR1 or by the activated forms of oncogenes is sufficient to induce VEGF and hence angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12554695     DOI: 10.1096/fj.02-0316com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  31 in total

1.  Inhibition of tissue factor by ixolaris reduces primary tumor growth and experimental metastasis in a murine model of melanoma.

Authors:  Andreia Da Silva de Oliveira; Luize G Lima; Andréa Mariano-Oliveira; Daniel E Machado; Luiz E Nasciutti; John F Andersen; Lars C Petersen; Ivo M B Francischetti; Robson Q Monteiro
Journal:  Thromb Res       Date:  2012-06-09       Impact factor: 3.944

2.  Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets.

Authors:  Li Ma; Rafael Perini; Webb McKnight; Michael Dicay; Andre Klein; Morley D Hollenberg; John L Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-22       Impact factor: 11.205

3.  Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis.

Authors:  Xiaotun Zhang; Wenbin Wang; Lawrence D True; Robert L Vessella; Thomas K Takayama
Journal:  Prostate       Date:  2009-05-15       Impact factor: 4.104

4.  Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?

Authors:  S Karabulut; E Akşit; F Tas; R Ciftci; A Aydiner; I Yildiz; S Keskin; Y Eralp; C T Yasasever; S Vatansever; R Disci; P Saip
Journal:  Tumour Biol       Date:  2014-01-05

5.  Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice.

Authors:  G N Adams; B K Sharma; L Rosenfeldt; M Frederick; M J Flick; D P Witte; L O Mosnier; E Harmel-Laws; K A Steinbrecher; J S Palumbo
Journal:  J Thromb Haemost       Date:  2018-09-27       Impact factor: 5.824

6.  Oral thrombostatin FM19 inhibits prostate cancer.

Authors:  Marvin T Nieman; Gretchen LaRusch; Chao Fang; Yihua Zhou; Alvin H Schmaier
Journal:  Thromb Haemost       Date:  2010-09-30       Impact factor: 5.249

7.  ncRuPAR inhibits gastric cancer progression by down-regulating protease-activated receptor-1.

Authors:  Long Liu; Bing Yan; Zhihui Yang; Xiaodong Zhang; Qunhao Gu; Xiaoqiang Yue
Journal:  Tumour Biol       Date:  2014-05-12

8.  Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model.

Authors:  T C Carneiro-Lobo; S Konig; D E Machado; L E Nasciutti; M F Forni; I M B Francischetti; M C Sogayar; R Q Monteiro
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

Review 9.  G-protein-coupled receptors and melanoma.

Authors:  Hwa Jin Lee; Brian Wall; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2008-05-27       Impact factor: 4.693

10.  Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic significance.

Authors:  Marta Tiburcio; Sandra M A Costa; Maria DE Fatima Duarte; Fernando C Schmitt; Adhemar Longatto Filho
Journal:  Oncol Lett       Date:  2012-07-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.